GABELLI & Co INVESTMENT ADVISERS INC. Acquires Shares of 42,901 Entellus Medical Inc (ENTL)

GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Entellus Medical Inc (NASDAQ:ENTL) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 42,901 shares of the medical technology company’s stock, valued at approximately $1,046,000.

Other hedge funds have also added to or reduced their stakes in the company. Nationwide Fund Advisors lifted its stake in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock valued at $168,000 after purchasing an additional 5,605 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after purchasing an additional 4,533 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Entellus Medical in the 2nd quarter valued at $199,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Entellus Medical by 74.7% in the 3rd quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock valued at $209,000 after purchasing an additional 4,846 shares during the last quarter. 74.02% of the stock is owned by institutional investors and hedge funds.

In other news, VP Thomas P. Williamson sold 2,449 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $24.08, for a total transaction of $58,971.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert S. White sold 3,471 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $83,338.71. The disclosure for this sale can be found here. In the last three months, insiders have sold 108,942 shares of company stock valued at $2,599,658. Company insiders own 7.70% of the company’s stock.

Entellus Medical Inc (NASDAQ ENTL) opened at $24.09 on Monday. The firm has a market cap of $613.67, a price-to-earnings ratio of -18.82 and a beta of -0.02. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 52-week low of $11.47 and a 52-week high of $25.58.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. BidaskClub lowered shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 16th. William Blair lowered shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $19.25.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2018/02/05/gabelli-co-investment-advisers-inc-acquires-shares-of-42901-entellus-medical-inc-entl.html.

Entellus Medical Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical Inc (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply